- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Sun Shield: Protecting Beyond Ultraviolet Light : Episode 2
Opinion
Video
Sunscreen Ingredients for UV and Visible Light Protection
Author(s):
An expert discusses how UV radiation causes DNA damage, accelerating skin aging and cancer risk. Visible light and infrared radiation induce oxidative stress and hyperpigmentation, especially in darker skin tones. Conventional sunscreens shield against UV radiation but offer limited visible light and infrared protection. Mineral filters (zinc oxide, titanium dioxide) provide broad coverage, while chemical filters (oxybenzone, avobenzone) absorb UV radiation but lack efficacy against visible and infrared radiation.
Video Player is loading.
Video content above is prompted by the following:
- How do the effects of visible light and infrared radiation on skin health compare with the effects of UV radiation?
- Are there specific populations or skin types more vulnerable to the effects of visible light?
- How do conventional sunscreens protect against UV radiation, and what are their limitations regarding visible light and infrared radiation?
- Physical/mineral (zinc oxide, titanium dioxide)
- Chemical (oxybenzone, avobenzone, etc)
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Related Content
